Compare Medtronic PLC (MDT) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Okta, Inc. — how do they compare? Medtronic PLC trades at $88.67 (market cap $112.24B), while Okta, Inc. trades at $232.16 (market cap $38.50B). The key difference: Medtronic PLC is far larger — about 2.9× Okta, Inc.'s market cap, and Medtronic PLC pays a 3.28% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Okta, Inc. for 44 Days on average.
| MDT | OKTA | |
|---|---|---|
Market Cap | $112.24B | $38.50B |
Volume | 105,663,236 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $105.35 | $220.21 |
52-Week Low | $73.75 | $62.93 |
Typical Hold Time | 63 Days | 44 Days |
Enterprise Value | $131.58B | $36.25B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
OKTA's stock trades at $232.13, up 6.48% in the last 24 hours, reflecting strong momentum. The technical outlook is bullish, with the price near resistance at $232. Recent earnings beats and a strategic focus on AI agent security, highlighted at the Oktane 2026 conference, support positive sentiment. However, valuation ratios like a P/E of 132.66 and P/S of 12.74 indicate a premium, while the company has only recently achieved profitability with a net income margin of 1.07% in 2025.
The outlook is cautiously optimistic, driven by revenue growth and AI positioning, but high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a 73.58% buy rating, though the current price exceeds the consensus target of $201.30, suggesting near-term consolidation may occur. Investors should weigh growth potential against premium multiples and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
